CAJ | 학술논문

目的：探讨卡托普利、安体舒通联合治疗慢性肺源性心脏病的疗效。方法：104例慢性肺源性心脏病患者，随机分为对照组及治疗组，每组52例，两组患者均实施常规治疗措施，治疗组在此基础上给予卡托普利联合安体舒通治疗20天，比较分析两组患者临床疗效及不良反应发生情况。结果：治疗组总有效率为90.4%，显著高于对照组的57.7%(P<0.05)；两组患者均未出现严重不良反应，所有患者均成功完成所有疗程。结论：卡托普利、安体舒通联合治疗慢性肺源性心脏病治疗效果显著。
목적：탐토잡탁보리、안체서통연합치료만성폐원성심장병적료효。방법：104례만성폐원성심장병환자，수궤분위대조조급치료조，매조52례，량조환자균실시상규치료조시，치료조재차기출상급여잡탁보리연합안체서통치료20천，비교분석량조환자림상료효급불량반응발생정황。결과：치료조총유효솔위90.4%，현저고우대조조적57.7%(P<0.05)；량조환자균미출현엄중불량반응，소유환자균성공완성소유료정。결론：잡탁보리、안체서통연합치료만성폐원성심장병치료효과현저。
Objective:To investigate the treatment of chronic pulmonary heart disease after using captopril and spironolactone. Methods:A total of 104 patients with chronic pulmonary heart disease was studied,Which were divided into control group(52 cases) and treatment groups (52 cases)atrandom.Two groups were given the conventional treatment;the treatment group was given captopril and spironolactone based on the conventional treatment.Both of the groups were observed after 20 days of treatment.Results:The rate of the total efficiency in the treatment group was 90.4%compared with the control group 57.7%.The efficacy of the two groups was significant different(P<0.05).In the course of treatment,the two groups have no severe reaction.Conclusions:Captopril and spironolactone are effective in the efficacy of treatment of chronic pulmonary heart disease significantly.